We are live on ! Find out more

Repligen

RGEN

Market cap $11.2B

176.94 USD

-11.70

6.2%

At close Updated Oct 30, 4:00 PM EDT

Pre-market

After hours

176.94

0.00

0%

1 day

-6.2%

5 days

0.01%

1 month

-7.95%

3 months

23.22%

6 months

49.56%

Year to date

7.66%

1 year

22.39%

5 years

-41.89%

10 years

519.32%

About: Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, and other life science companies. It sells four main product categories: filtration and fluid management is the largest category (about 55% of total revenue), while chromatography, proteins, and process analytics are 21%, 11%, and 13%, respectively. Customers in North America, Europe, and Asia-Pacific contribute about 44%, 37%, and 19% of revenue, respectively.

Employees: 2,000

Healthcare Medical Instruments & Supplies

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 42.1%

Neutral 47.4%

Negative 10.5%

Repligen Announces $1 Billion Private Convertible Senior Notes Transaction

WALTHAM, Mass., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) (“Repligen”), today announced that it entered into privately negotiated exchange and/or subscription agreements with certain holders of its outstanding 1.00% Convertible Senior Notes due 2028 (the “2028 Notes”) and certain new investors, pursuant to which Repligen will issue $1.0 billion aggregate principal amount of 0.25% Convertible Senior Notes due 2031 (the “New Notes”). Approximately $541.4 million principal amount of the New Notes will be issued in exchange for approximately $456.8 million principal amount of 2028 Notes (the “Exchange Transactions”) and approximately $458.6 million principal amount of the New Notes will be issued for cash (the “Subscription Transactions”, and together with the Exchange Transactions, the “Transactions”). The conversion price for the New Notes will initially be approximately $226.37 per share of Repligen's common stock, which represents a conversion premium of approximately 20% over the closing price of Repligen's common stock on October 29, 2026, subject to customary anti-dilution adjustments. Following the closing of the Transactions, which is expected to occur on or about November 6, 2026, subject to customary closing conditions, approximately $143.2 million in aggregate principal amount of 2028 Notes will remain outstanding with terms unchanged.

Repligen Announces $1 Billion Private Convertible Senior Notes Transaction

Conestoga Micro Cap Composite: Q3 2026 Leaders, Laggards, Buys And Sells

We remain encouraged by the operational performance of the Micro cap companies held in portfolios. TWST shares surged as a strong fiscal 3Q highlighted accelerating demand across several of the company's end markets. TKNO management responded to the stronger first half by substantially raising its full-year revenue outlook.

Conestoga Micro Cap Composite: Q3 2026 Leaders, Laggards, Buys And Sells

Repligen Corporation (RGEN) Q3 2026 Earnings Call Transcript

Repligen Corporation (RGEN) Q3 2026 Earnings Call Transcript

Repligen Corporation (RGEN) Q3 2026 Earnings Call Transcript

What Repligen (RGEN) Said on Its Q3 Earnings Call

Repligen NASDAQ: RGEN reported record third-quarter 2026 revenue of $209 million, surpassing its prior quarterly peak set in the second quarter of 2022, as growth in its Proteins, Chromatography and Analytics franchises offset weakness in Filtration.

What Repligen (RGEN) Said on Its Q3 Earnings Call

Conestoga Small Cap Composite Q3 2026 Portfolio Activity

The Conestoga Small Cap Composite returned -11.22% net of fees in 3Q26, trailing the -9.39% return for the Russell 2000 Growth Index. Small Cap Composite top 5 leaders include Repligen, Merit Medical, Stevanato Group, Descartes Systems and Digi International. Small Cap Composite bottom 5 laggards include Mercury Systems, AAON, RBC Bearings, SPX Technologies and UL Solutions.

Conestoga Small Cap Composite Q3 2026 Portfolio Activity

Zacks Investment Research

Repligen (RGEN) Q3 Earnings and Revenues Surpass Estimates

Repligen (RGEN) came out with quarterly earnings of $0.53 per share, beating the Zacks Consensus Estimate of $0.46 per share. This compares to earnings of $0.46 per share a year ago.

Repligen (RGEN) Q3 Earnings and Revenues Surpass Estimates

Repligen Reports Third Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance

Third quarter revenue of $209 million, a year-over-year increase of 11% as reported and 12.5% organic Closed BioLife acquisition, which fast-tracks Repligen's leadership and offering in high-growth cell therapy market Raising FY26 revenue guidance to $844-$852 million which represents reported revenue growth of 14.5% - 15.5% WALTHAM, Mass., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), today reported financial results for its third quarter of 2026, covering the three-month period ended September 30, 2026.

Repligen Reports Third Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance

Baron Health Care Fund Q3 2026 Top Contributors And Detractors

TMO's organic growth of 5% exceeded consensus by 200 basis points, and management raised full-year organic growth guidance/. MTD's local-currency sales grew 6%, exceeding prior guidance of 3%. TEVA management raised guidance for all three brands.

Baron Health Care Fund Q3 2026 Top Contributors And Detractors

Repligen: A Buy As Its Growth Engine Gears Up

Repligen demonstrates 13% organic growth despite Filtration headwinds, with strong momentum in the Proteins and Process Analytics segments. Filtration's drag is temporary, with mid-single-digit growth expected in 2026 and order activity fueling a robust 2027 backlog. The BioLife acquisition adds high-margin, sticky cell therapy consumables, with anticipated synergies and accretive EPS contributions post-closing.

Repligen: A Buy As Its Growth Engine Gears Up

Repligen to Report Third Quarter 2026 Financial Results

WALTHAM, Mass., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), today announced that the Company will report its third quarter 2026 financial results on Tuesday, October 27, 2026.

Repligen to Report Third Quarter 2026 Financial Results

See News Rankings

Price charts implemented using Lightweight Charts™